-
Studies to be presented by Providence researchers at AACR annual meeting
The annual AACR meeting draws the most innovative cancer researchers seeking breakthroughs in treatments.
-
Seeking better treatments for people with ER+/HER- breast cancer
Two studies for people with ER+/HER2- breast cancer are enrolling patients at Providence Cancer Institute.
-
From life-saving surgery to back on the slopes: A photographer’s story
Gary tells his story about the difficult journey back to the slopes of Mt. Hood after receiving life-saving surgery for pancreatic cancer.
-
Robotic versus open surgery for early cervical cancer
This is an exciting new trial comparing robotic assisted laparoscopy to open hysterectomy and lymph node assessment for the treatment of early-stage cervical cancer.
-
A year to remember: Advancements, recognition and transitions
Catch the 2024 highlights from Providence Cancer Institute in this year-end recap focused on research advancements, caregiver recognition and community engagement.
-
CAR T cell-therapy, hope and healing: Dean’s story
Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.
-
Two clinical trials for solid tumor cancers take different approaches to stop growth
Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.
-
Leadership change at Providence Cancer Institute, #FINISHCANCER goal remains
R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.
-
Harnessing CAR T-cell therapy: A new study for indolent B-cell non-Hodgkin lymphoma
New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.
-
New studies test immunotherapy to boost breast cancer treatment and prevent return
Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.
-
Attend a free virtual symposium on melanoma, Oct. 25
Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.
-
Prostate cancer study includes a tumor test to personalize treatment
A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.
-
Dr. Walter Urba announces retirement from Providence
Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.
-
Dr. Bernard Fox honored for his lifetime contributions to cancer research
Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.
-
Can these new studies offer hope for people with lung and head and neck cancers?
A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.
-
Cancer survivor speaks with doctor he credits for saving his life
Cancer survivor Mark Williams chats with Dr. Brendan Curti about
-
2024 Hood to Coast Relay: Providence team captains tell us why they run
What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.
-
Promising advances in treating TNBC: Two studies offer hope
Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.
-
Targeting cancer cells: Two studies take different approaches
A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec
-
The evolution of cancer immunotherapy: Dr. Urba shares his insights
Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.
-
Loading More...